The offer document regarding the acquisition of Pulsion Medical Systems SE now published
As earlier communicated, Getinge has decided to issue a public tender offer to acquire all shares in Pulsion Medical Systems SE (“Pulsion”), listed on the German Stock Exchange (Deutsche Börse).
As part of the acquisition process, the publication of the offer document has now been approved by the German Federal Financial Supervisory Authority (BaFin) and is available on www.maquet.com/pulsion-angebot.
The acceptance period commences today and will expire on 12 February 2014. The price of 16.90 € represents a premium of approximately 22 % on the weighted average share price of the Pulsion shares during the three-month period ending on 3 December 2013.
The public tender offer is subject to conditions that include the following: clearance by the German Federal Cartel Office (Bundeskartellamt) and a minimum acceptance threshold of at least 75% of the Pulsion shares. Further conditions and information pertaining to the public tender offer are set forth in the offer document.
Getinge has already secured the acquisition of 74.6% of the shares in Pulsion.
For futher information please contact:
Ulf Grunander
CFO, Getinge Group
Telefon: +46 10 335 55 80
E-post: ulf.grunander@getinge.com
Disclaimer
This announcement is for information purposes only. The offer is exclusively made by and subject to the terms and conditions are set forth in the offer document (“Offer Document”).
Shareholders of Pulsion are strongly advised to carefully read the Offer Document, as well as any related documents, since all of the a foregoing will contain important information. They are furthermore advised to seek independent advice, in order to reach an informed decision in respect of the content of the Offer Document and with regard to the corresponding public offer.
The offer is issued exclusively under the laws of the Federal Republic of Germany, in particular, in accordance with the German Securities and Takeover Act (“WpÜG”), and the Regulation on the Content of Offer Documents, Consideration for Takeover Offers and Mandatory Offers and the Release from the Obligation to Publish and Issue an Offer (WpÜG Offer Regulation).
The offer will not be implemented and executed in accordance with the laws of jurisdictions other than the Federal Republic of Germany. Thus, no other announcements, registrations, admissions or approvals of the offer document outside the Federal Republic of Germany have been or will be filed, arranged for or granted. No Pulsion shareholders have recourse to investor protection laws/provisions in any jurisdiction other than the Federal Republic of Germany. Getinge has not approved the publication, sending, distribution, or dissemination by third parties of this announcement or any other document associated with the offer outside the Federal Republic of Germany, as the release, publication or distribution of this announcement in certain jurisdictions other than the Federal Republic of Germany may be restricted by law. Persons who are not resident in the Federal Republic of Germany or who are subject to the laws of other jurisdictions should inform themselves of, and observe, any corresponding applicable requirements.
Neither Getinge nor persons acting in concert with Getinge within the meaning of section 2 para. 5 of WpÜG are in any way responsible for the compliance with the laws of any jurisdiction other than those of the Federal Republic of Germany, of the publication, sending, distribution, or dissemination by a third party of this announcement or any other document associated with the offer.
GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions, interventional cardiology and intensive care.
The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.
Tags: